|1.||Xi, Guohua: 21 articles (01/2016 - 02/2002)|
|2.||Keep, Richard F: 20 articles (01/2016 - 02/2002)|
|3.||Hua, Ya: 20 articles (01/2016 - 02/2002)|
|4.||Kontoghiorghes, George J: 20 articles (09/2013 - 01/2003)|
|5.||Dal-Pizzol, Felipe: 14 articles (07/2015 - 02/2004)|
|6.||Pennell, Dudley J: 13 articles (09/2015 - 08/2002)|
|7.||Galanello, Renzo: 13 articles (07/2013 - 10/2005)|
|8.||Piga, Antonio: 12 articles (09/2015 - 10/2004)|
|9.||Porter, John B: 12 articles (09/2015 - 11/2004)|
|10.||Richardson, Des R: 12 articles (01/2015 - 01/2003)|
03/01/2006 - "Intermittent very high-dose intravenous deferoxamine is practical, safe, and effective in managing iron overload in children. "
10/01/2001 - "Intravenous administration of high-dose deferoxamine over 48 h per week using a portable pump and implanted chamber improved compliance in two thalassemic adult patients, resulting in a significant decrease in iron overload. "
01/01/1999 - "Therapy with the chelator device having immobilized desferrioxamine should be beneficial for treatment of patients with iron overload."
06/06/1987 - "Subcutaneous desferrioxamine, though effective in preventing or reducing iron overload in transfusion-dependent refractory anaemia, is expensive and inconvenient. "
10/08/1983 - "Only one compound, deferrioxamine B, has been shown to be clinically effective and well tolerated in humans suffering from chronic iron overload. "
04/01/2006 - "Treatment with deferoxamine significantly decreased the size of brain damage (-28%) after ischemia and improved behavioral recovery. "
07/01/1992 - "Deferoxamine significantly improved systolic function in both newborn and adult hearts (p less than 0.01) exposed to 40 minutes of ischemia. "
03/01/1992 - "Deferoxamine given as pretreatment 1 hour before ischemia at doses of 30 mg/kg, and perhaps as low as 10 mg/kg, significantly improved survival. "
04/01/1995 - "This study tested the hypothesis that pretreatment with free deferoxamine ameliorates metabolic decay and delayed hypoperfusion after global hyperglycemic ischemia. "
06/01/2014 - "Desferrioxamine effectively attenuates testicular tissue at the end of 3 h of ischemia but not in an equal period of reperfusion."
|3.||beta-Thalassemia (Cooley's Anemia)
07/01/2004 - "High doses of intravenous deferoxamine via central venous line (CVL) has recently been shown to improve survival in patients with noncompliant thalassemia major (TM). "
01/01/1994 - "In vitro deferoxamine partially improved monocyte phagolysosomal fusion of patients with thalassemia major, and did not affect monocyte function in carriers and healthy subjects. "
01/01/2010 - "There are limited studies on renal involvement in beta-thalassemia, mainly involving patients on deferoxamine, reporting both glomerular and tubular dysfunction. "
05/01/2009 - "In conclusion, the results of this study show that the risk factors for predicting mortality in patients with thalassemia major are deferoxamine-treatment, complications, and the interaction effect of sex and age."
01/01/2001 - "In more recent studies with homozygous beta-thalassemia, using continuous Intravenous deferoxamine infusion at 50 mg/kg/d, and initial elimination half-life of 0.28/h and steady-state concentration of 7 micromol/L were observed. "
05/01/2006 - "Deferoxamine (DFO) therapy has been associated with improved survival of thalassemia patients. "
01/01/2015 - "desferrioxamine (DFO) twice weekly were given to transfusion-dependent β-thalassemia children. "
01/01/2014 - "A 53-year-old man with history of β-thalassemia presented with decreased vision in both eyes 1 month after initiating deferoxamine therapy. "
08/01/2012 - "To describe and classify patterns of abnormal fundus autofluorescence (FAF) of patients with β-thalassemia receiving long-term treatment with deferoxamine (DFO). "
07/01/2012 - "This was a cross-sectional study of 382 TM patients treated with regular transfusions and desferrioxamine at the Thalassemia Center in Dubai, UAE. "
09/01/1991 - "Despite substantial reduction in infarct size previously observed at 4 h following reflow with the same dose and regimen of desferrioxamine treatment, results of the present study indicate that desferrioxamine did not provide sustained protection against myocardial ischaemia-reperfusion injury. "
04/01/1996 - "In this study, we evaluated the effects of deferoxamine, an antioxidant, on recovery from ischemia/reperfusion injury after nerve compression. "
06/01/2011 - "Deferoxamine mesylate is known to ameliorate tissue ischemia-reperfusion injury. "
01/01/1999 - "Effect of deferoxamine on post-hypoxic-ischemic reperfusion injury of the newborn lamb heart."
11/01/1996 - "Attenuation of reperfusion injury by conjugated deferoxamine."
|1.||Chelation Therapy (Therapy, Chelation)
|3.||Blood Transfusion (Blood Transfusions)
|4.||Renal Dialysis (Hemodialysis)